Sep 9 |
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
|
Sep 5 |
RedHill Biopharma regains compliance with Nasdaq
|
Sep 5 |
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
Aug 29 |
RedHill Biopharma Announces First Half 2024 Business Highlights
|
Aug 21 |
Three Undiscovered Gems in the United States Market
|
Aug 21 |
Talicia® Launched in the United Arab Emirates
|
Aug 19 |
RedHill shares climb on results indicating potential use of opaganib for obesity-related disorders
|
Aug 19 |
Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested
|
Aug 19 |
RedHill Announces Positive Obesity and Diabetes Results with Opaganib
|
Aug 16 |
RedHill Biopharma plans to implement ADS ratio change
|